Patents Assigned to Sanochemia Pharmazeutika AG
-
Patent number: 10265397Abstract: Photodynamic therapy of tumors such as bladder tumors includes photosensitizing with a photosensitizer that is a complex or a compound of hypericin and a polymeric complexing agent. The photosensitizer is formed from an alkali salt of hypericin and the polymeric complexing agent. The alkali salt of hypericin is a sodium salt or a potassium salt. The complexing agent is a polyethylene glycol or a poly-N-vinyl amide.Type: GrantFiled: November 7, 2017Date of Patent: April 23, 2019Assignee: SANOCHEMIA PHARMAZEUTIKA AGInventors: Stefan Welzig, Gregor Medinger, Beate Kálz, József Gungl, Klaus Gerdes, Werner Frantsits, Christina Abrahamsberg
-
Patent number: 10201609Abstract: Photodynamic therapy of tumors such as bladder tumors includes photosensitizing with a photosensitizer that is a complex or a compound of hypericin and a polymeric complexing agent. The photosensitizer is formed from an alkali salt of hypericin and the polymeric complexing agent. The alkali salt of hypericin is a sodium salt or a potassium salt. The complexing agent is a polyethylene glycol or a poly-N-vinyl amide.Type: GrantFiled: November 7, 2017Date of Patent: February 12, 2019Assignee: SANOCHEMIA PHARMAZEUTIKA AGInventors: Stefan Welzig, Gregor Medinger, Beate Kälz, József Gungl, Klaus Gerdes, Werner Frantsits, Christina Abrahamsberg
-
Patent number: 10143751Abstract: Photodynamic therapy of tumors such as bladder tumors includes photosensitizing with a photosensitizer that is a complex or a compound of hypericin and a polymeric complexing agent. The photosensitizer is formed from an alkali salt of hypericin and the polymeric complexing agent. The alkali salt of hypericin is a sodium salt or a potassium salt. The complexing agent is a polyethylene glycol or a poly-N-vinyl amide.Type: GrantFiled: October 8, 2015Date of Patent: December 4, 2018Assignee: SANOCHEMIA PHARMAZEUTIKA AGInventors: Stefan Welzig, Gregor Medinger, Beate Kalz, Jozsef Gungl, Klaus Gerdes, Werner Frantsits, Christina Abrahamsberg
-
Patent number: 10064961Abstract: A method for producing a liquid pharmaceutical preparation which contains a complex consisting of DOTA and gadolinium and a base such as L-lysine or meglumine, includes the following steps: a) An aqueous solution containing free DOTA, free gadolinium and a base such as L-lysine or meglumine is produced. b) The yield of free DOTA and free gadolinium is determined in the solution obtained according to step a). c) Free gadolinium and/or free DOTA is added in order to adjust a stoichiometric excess of free DOTA in the solution. d) The complexation is executed at an increased temperature. e) Additional base such as L-lysine or meglumine is added in order to adjust the pH value. f) The final volume of the preparation is adjusted.Type: GrantFiled: June 15, 2015Date of Patent: September 4, 2018Assignee: SANOCHEMIA PHARMAZEUTIKA AGInventors: Stefan Welzig, Raffael Schuecker, Beate Kaelz, Jozsef Gungl, Klaus Gerdes, Roswitha Braunrath
-
Patent number: 9775900Abstract: In the early detection of cancer, in particular bladder cancer, a photodynamic diagnosis uses, as a photosensitizer, a formulation that contains sodium hypericinate that is bonded to polyvinylpyrrolidone or complexed with polyvinylpyrrolidone.Type: GrantFiled: March 27, 2017Date of Patent: October 3, 2017Assignee: SANOCHEMIA PHARMAZEUTIKA AGInventors: Stefan Welzig, Beate Kälz, József Gungl, Klaus Gerdes, Werner Frantsits, Christina Abrahamsberg
-
Patent number: 9675598Abstract: The present disclosure relates to tolperisone, or a pharmaceutically acceptable salt or hydrate thereof, with 10 ppm 2-methyl-1-(4-methylphenyl)-propenone (4-MMPPO) or less, methods of producing the same, as well as compositions related thereto. The disclosure further relates to methods of treating a subject with tolperisone under conditions that limit exposure of the subject to tolerable levels of 4-MMPPO.Type: GrantFiled: August 1, 2016Date of Patent: June 13, 2017Assignee: Sanochemia Pharmazeutika AGInventors: Federico Gaeta, Klaus Gerdes, Stefan Welzig, Beate Katz, Jan Rothenburger, Jozsef Gungl
-
Patent number: 9662317Abstract: The present disclosure relates to methods of administering tolperisone to subjects in need thereof. In certain aspects, the present disclosure relates to methods of administering tolperisone to subjects in need thereof, said methods limiting the exposure of the subject to 4-MMPPO.Type: GrantFiled: March 11, 2016Date of Patent: May 30, 2017Assignee: SANOCHEMIA PHARMAZEUTIKA AGInventors: Federico Gaeta, Klaus Gerdes, Stefan Welzig, Beate Katz, Jan Rothenburger, Jozsef Gungl
-
Patent number: 9629932Abstract: In the early detection of cancer, in particular bladder cancer, a photodynamic diagnosis uses, as a photosensitizer, a formulation that contains sodium hypericinate that is bonded to polyvinylpyrrolidone or complexed with polyvinylpyrrolidone.Type: GrantFiled: October 8, 2015Date of Patent: April 25, 2017Assignee: SANOCHEMIA PHARMAZEUTIKA AGInventors: Stefan Welzig, Beate Kalz, Jozsef Gungl, Klaus Gerdes, Werner Frantsits, Christina Abrahamsberg
-
Publication number: 20160367540Abstract: The present disclosure relates to tolperisone, or a pharmaceutically acceptable salt or hydrate thereof, with 10 ppm 2-methyl-1-(4-methylphenyl)-propenone (4-MMPPO) or less, methods of producing the same, as well as compositions related thereto. The disclosure further relates to methods of treating a subject with tolperisone under conditions that limit exposure of the subject to tolerable levels of 4-MMPPO.Type: ApplicationFiled: August 1, 2016Publication date: December 22, 2016Applicant: SANOCHEMIA PHARMAZEUTIKA AGInventors: Federico Gaeta, Klaus Gerdes, Stefan Welzig, Beate Katz, Jan Rothenburger, Jozsef Gungl
-
Publication number: 20160220549Abstract: The present disclosure relates to methods of administering tolperisone to subjects in need thereof. In certain aspects, the present disclosure relates to methods of administering tolperisone to subjects in need thereof, said methods limiting the exposure of the subject to 4-MMPPO.Type: ApplicationFiled: March 11, 2016Publication date: August 4, 2016Applicant: SANOCHEMIA PHARMAZEUTIKA AGInventors: Federico Gaeta, Klaus Gerdes, Stefan Welzig, Beate Katz, Jan Rothenburger, Jozsef Gungl
-
Patent number: 9315480Abstract: The present disclosure is directed to methods for providing tolperisone having extremely low levels of 4-MMPPO (2-methyl-1-(4-methylphenyl)-propenone), as well as related compositions. The invention further relates to methods of treating a subject with tolperisone under conditions that limit exposure of the subject to tolerable levels of 4-MMPPO, among other features.Type: GrantFiled: April 24, 2008Date of Patent: April 19, 2016Assignee: SANOCHEMIA PHARMAZEUTIKA AGInventors: Federico Gaeta, Klaus Gerdes, Stefan Welzig, Beate Kalz, Jan Rothenburger, József Gungl
-
Patent number: 8372979Abstract: The invention relates to a method for producing highly pure 2,4?-dimethyl-3-piperidino-propiophenone (tolperisone) (formula I) and the pharmaceutically acceptable salts, hydrochlorides, and hydrates thereof. The method allows the content of the undesired byproduct 2-methyl-1-(4-methylphenyl) propenone (4-MMPPO) to be kept significantly lower than in previously known methods. The invention further relates to active substance formulations which contain tolperisone and are suitable, among other things, for producing combination preparations used for treating patients suffering from Alzheimer's disease. The invention also relates to topical formulations, controlled release (CR) formulations, and transdermal therapeutic systems, such as active substance patches, which contain less than 50 ppm, preferably less than 10 ppm, more preferably less than 7 ppm, and most preferably less than 3 ppm or 0 ppm (i.e.Type: GrantFiled: April 24, 2008Date of Patent: February 12, 2013Assignee: SANOCHEMIA Pharmazeutika AGInventors: Stefan Welzig, Jan Rothenburger, Beate Kälz, József Gungl, Klaus Gerdes, Federico Gaeta
-
Patent number: 8212029Abstract: A process for the production of extremely pure galanthamine and galanthamine derivatives is provided. Racemic bromine narwedine is debrominated under palladium catalysis. The reaction mixture is then worked-up in the presence of oxygen or peroxides so that the palladium catalyst is converted into an insoluble form that can be easily separated. Further reaction is carried out by reduction of enantiomerically pure narwedine to form enantiomerically pure galanthamine, which is then alkylated or dealkylated, so that a corresponding substitution on the ring-nitrogen atom is achieved. By further purification, such as recrystallization, residual portions of palladium of below 5 ppm are achieved. The pure galanthamine can then be directly used as a pharmaceutical raw material.Type: GrantFiled: February 14, 2008Date of Patent: July 3, 2012Assignee: Sanochemia Pharmazeutika AGInventors: Stefan Welzig, Anton Gerdenitsch, Jan Rothenburger, Susanne Kolar, Alexandra Scherleithner
-
Publication number: 20100249423Abstract: A GRDDS (Gastro Retentive Drug Delivery System) containing tolperisone and having a 2-methyl-1-(4-methylphenyl)-propenone (4-MMPPO) fraction of less than 1.5 ppm for the extended release of the active substance tolperisone while avoiding the formation of 4-MMPPO in the gastrointestinal tract.Type: ApplicationFiled: February 19, 2010Publication date: September 30, 2010Applicant: SANOCHEMIA PHARMAZEUTIKA AGInventors: Stefan Welzig, Jan Rothenburger, Beate Kälz, József Gungl, Klaus Gerdes
-
Publication number: 20100150995Abstract: The invention relates to a method for producing highly pure 2,4?-dimethyl-3-piperidino-propiophenone (tolperisone) (formula I) and the pharmaceutically acceptable salts, hydrochlorides, and hydrates thereof. The method allows the content of the undesired byproduct 2-methyl-1-(4-methylphenyl) propenone (4-MMPPO) to be kept significantly lower than in previously known methods. The invention further relates to active substance formulations which contain tolperisone and are suitable, among other things, for producing combination preparations used for treating patients suffering from Alzheimer's disease. The invention also relates to topical formulations, controlled release (CR) formulations, and transdermal therapeutic systems, such as active substance patches, which contain less than 50 ppm, preferably less than 10 ppm, more preferably less than 7 ppm, and most preferably less than 3 ppm or 0 ppm (i.e.Type: ApplicationFiled: April 24, 2008Publication date: June 17, 2010Applicant: SANOCHEMIA PHARMAZEUTIKA AGInventors: Stefan Welzig, Jan Rothenburger, Beate Kalz, Jozsef Gungl, Klaus Gerdes, Federico Gaeta
-
Publication number: 20100105895Abstract: A process for the production of extremely pure galanthamine or extremely pure galanthamine derivatives, whereby a start is made from racemic bromine narwedine, which is debrominated under palladium catalysis. The working-up of the reaction mixture, which is carried out in the presence of oxygen or peroxides, is essential to the process, so that the palladium catalyst is converted into an insoluble form, a form that can be easily separated. The further reaction is carried out by reduction of enantiomerically pure narwedine to form enantiomerically pure galanthamine, whereby it is then alkylated or dealkylated, so that a corresponding substitution on the ring-nitrogen atom is achieved. By further purification, such as recrystallization, residual portions of palladium of below 5 ppm are achieved, so that the direct use as a pharmaceutical raw material is made possible.Type: ApplicationFiled: February 14, 2008Publication date: April 29, 2010Applicant: SANOCHEMIA PHARMAZEUTIKA AGInventors: Stefan Welzig, Anton Gerdenitsch, Jan Rothenburger, Susanne Kolar, Alexandra Scherleithner
-
Publication number: 20090326219Abstract: A process for the production of extremely pure galanthamine or extremely pure galanthamine derivatives, a start is made from racemic bromine narwedine, which is debrominated under palladium catalysis. In this case, the working-up of the reaction mixture, which is carried out in the presence of oxygen or peroxides so that the palladium catalyst in an insoluble form is converted into an easily separable form, is essential. The further reaction is carried out by reduction of enantiomer-pure narwedine to form enantiomer-pure galanthamine, whereby it is then alkylated or dealkylated so that a corresponding substitution on the ring-nitrogen atom is achieved. By further purification, such as recrystallization, residual portions of palladium of below 5 ppm are achieved, so that direct use as a pharmaceutical raw material is made possible.Type: ApplicationFiled: June 26, 2009Publication date: December 31, 2009Applicant: SANOCHEMIA PHARMAZEUTIKA AGInventors: Klaus GERDES, József GUNGL, Beate KÄLZ, Jan ROTHENBURGER, Stefan WELZIG
-
Publication number: 20090253743Abstract: The present disclosure is directed to methods for providing tolperisone having extremely low levels of 4-MMPPO (2-methyl-1-(4-methylphenyl)-propenone), as well as related compositions. The invention further relates to methods of treating a subject with tolperisone under conditions that limit exposure of the subject to tolerable levels of 4-MMPPO, among other features.Type: ApplicationFiled: November 26, 2008Publication date: October 8, 2009Applicants: Avigen, Inc., Sanochemia Pharmazeutika, AGInventors: Federico Gaeta, Stefan Welzig, Jan Rothenburger, Beate Kalz, Jozsef Gungl, Klaus Gerdes
-
Publication number: 20090203920Abstract: The invention relates to a method for isolating 5-substituted tetrazoles of general formula (I) in which R represents a substituted biphenyl radical during which the ring closure, starting from a corresponding nitrile, is carried out in organic solvents while using alkali, alkaline-earth or organotin azides. The organic phases containing the nitrile and the tetrazol are firstly mixed with water while firstly forming three liquid phases, after which the aqueous phase containing the azide and the phase containing the nitrile are separated out, and the middle organic phase containing the tetrazol is subsequently processed. In the case of ester groups to be saponified, this phase is mixed with alkali lye, after which the organic phase is separated out and the aqueous phase is acidified or otherwise, this phase is immediately acidified and purified.Type: ApplicationFiled: August 3, 2006Publication date: August 13, 2009Applicant: SANOCHEMIA PHARMAZEUTIKA AGInventors: Stefan Welzig, Anton Gerdenitsch, Wolfgang Oberleitner
-
Publication number: 20080188522Abstract: The invention relates to a method for producing an acid addition salt of 2,4?-dimethyl-3-piperidino-propiophenone (tolperisone) with a pharmaceutically acceptable acid, of the formula (I). According to the invention, 4-methylpropiophenone is reacted with piperidine hydrochloride and 1,2-dioxolane in the presence of an acid serving as a catalyst, and the tolperisone obtained in the form of an acid addition salt is separated by filtering after the reaction mixture has cooled down.Type: ApplicationFiled: April 4, 2008Publication date: August 7, 2008Applicant: SANOCHEMIA PHARMAZEUTIKA AGInventors: Laszlo Czollner, Beate Kalz, Jan Rothenburger, Stefan Welzig